宫颈病变中HPV DNA检测与IHC检测P16蛋白的关联性研究

王皓晨, 贾利晴, 杨瑜, 王乾, 郁成礼, 田田, 毕蕊, 涂小予, 柏乾明, 朱晓丽, 周晓燕, 任敏

  1. 复旦大学附属肿瘤医院病理科,复旦大学医学院肿瘤学系,复旦大学病理研究所,上海 200032
  • 收稿日期:2024-11-13 修回日期:2025-02-06 出版日期:2025-03-30 发布日期:2025-04-10
  • 通信作者: 任敏
  • 作者简介:王皓晨(ORCID: 0000-0002-2440-2683),博士,主管技师。
  • 基金资助:
    上海市协同创新集群(2019CXJQ03);上海市科学技术委员会“ 科技创新行动计划”医学创新研究专项(20Z11900300)

摘要/Abstract

摘要:

背景与目的:人乳头状瘤病毒(human papilloma virus,HPV)感染状态在宫颈癌前病变诊断和宫颈癌分型中具有重要意义,而在宫颈病变中高危型(high-risk,HR)HPV感染通常与P16蛋白的过表达密切相关,因此在临床上对组织样本进行病理学诊断时将免疫组织化学(immunohistochemistry,IHC)检测的P16蛋白表达作为判断HPV感染情况的重要依据,但两者之间仍有部分不一致,其相关性有待深入研究,以更好地指导临床实践。方法:回顾性收集复旦大学附属肿瘤医院2020年1月—2023年12月进行宫颈活检或手术的618例患者的临床病理学资料(伦理批号:050432-4-2307E),采用聚合酶链反应(polymerase chain reaction,PCR)反向点杂交法检测HPV DNA多亚型,包括HR和低危型(low-risk,LR);采用IHC检测P16蛋白水平,比较两者的一致率,评估P16表达在判断HPV感染时的灵敏度和特异度。618例宫颈病变患者中,宫颈鳞癌92例,宫颈腺癌257例,高级别鳞状上皮内病变(high-grade squamous intraepithelial lesions,HSIL)79例,低级别鳞状上皮内病变(low-grade squamous intraepithelial lesions,LSIL)105例,慢性宫颈炎85例。结果:在宫颈鳞癌中,HR-HPV和P16的阳性率分别为88.0%(81/92)和91.3%(84/92),一致率为90.2%(83/92),P16在判断HR-HPV感染中的灵敏度和特异度为96.3%和45.5%;在宫颈腺癌中,HR-HPV和P16的阳性率分别为54.5%(140/257)和58.8%(151/257),一致率为82.5%(212/257),P16在判断HR-HPV感染中的灵敏度和特异度为87.9%和76.1%;在HSIL中,HR-HPV和P16的阳性率分别为75.9%(60/79)和70.9%(56/79),一致率为82.2%(65/79),P16在判断HR-HPV感染中的灵敏度和特异度为85.0%和73.7%;在LSIL中,HR-HPV和P16的阳性率分别为73.3%(77/105)和8.5%(9/105),一致率为33.3%(35/105),P16在判断HR-HPV感染中的灵敏度和特异度为10.4%和96.4%;在慢性宫颈炎中,HR-HPV和P16的阳性率分别为20.0%(17/85)和0.0%(0/85),一致率为80.0%(68/85),P16在判断HR-HPV感染中的灵敏度和特异度为0.0%和100.0%。在宫颈鳞癌、宫颈腺癌及HSIL中P16阳性与HPV16/18呈显著正相关(P=0.000),而在LSIL及慢性宫颈炎中无显著相关性(P>0.05)。结论:在宫颈鳞癌及宫颈腺癌中,P16阳性表达与HPV DNA阳性(HPV感染)的一致率较高,尤其P16表达与HPV16/18亚型感染显著相关。HSIL中P16阳性表达可以初步反映HPV感染情况,但在LSIL及慢性宫颈炎中,P16表达难以准确地反映HPV感染情况。P16与HPV DNA检测不一致可能受感染亚型、病理学类型、样本质量等多种因素影响,实际工作中应仔细分析或用多种方法确定HPV的感染状态。

关键词: 宫颈病变, 人乳头状瘤病毒, P16免疫组织化学, 宫颈鳞癌, 宫颈腺癌, 高级别鳞状上皮内病变, 低级别鳞状上皮内病变, 慢性宫颈炎, 一致率

Abstract:

Background and purpose: Human papilloma virus (HPV) infection status is crucial for diagnosing cervical precancerous lesions and classifying cervical cancer. High-risk (HR) HPV is often linked to P16 protein overexpression, so P16 detection via immunohistochemistry (IHC) is commonly used to assess HPV infection. However, the differences between HPV status and P16 expression remains unclear. An in-depth study of the correlation between HPV and P16 is essential for clinical guidance. Methods: We retrospectively collected clinical and pathological data of cervical lesions from 618 patients diagnosed at the Department of Pathology, Fudan University Shanghai Cancer Center from January 2020 to December 2023 (Ethical number: 050432-4-2307E). Polymerase chain reaction (PCR) reverse dot hybridization was used to detect HPV including HR and low-risk (LR) subtypes, and immunohistochemistry was used to detect P16 for comparative analysis. Based on different clinical and pathological diagnoses, the sensitivity and specificity of P16 expression in evaluating HPV infection were evaluated. Among the 618 cases of cervical lesions, there were 92 cases of cervical squamous cell carcinoma, 257 cases of cervical adenocarcinoma, 79 cases of high-grade squamous intraepithelial lesions (HSIL), 105 cases of low-grade squamous intraepithelial lesions (LSIL), and 85 cases of chronic cervical inflammation. Results: According to clinical diagnosis, the HR-HPV positive rate in cervical squamous cell carcinoma was 88.0% (81/92), the P16 positive rate was 91.3% (84/92), and the overall consistency rate between P16 and HPV detection was 90.2% (88/92); for HR-HPV infection, the sensitivity and specificity of P16 were 96.3% and 45.5%. The positive rate of HR-HPV in adenocarcinoma was 54.5% (140/257), the positive rate of P16 was 58.8% (151/257), and the overall consistency rate between P16 and HPV detection was 82.5% (212/257); for HR-HPV infection, the sensitivity and specificity of P16 were 87.9% and 76.1%. In HSIL, the HR-HPV positive rate was 75.9% (60/79), the positive rate of P16 was 70.9% (56/79), and the overall consistency rate between P16 and HR-HPV detection was 82.2% (65/79); for HR-HPV infection, the sensitivity and specificity of P16 were 85.0% and 73.7%. In LSIL, the HR-HPV positive rate was 73.3% (77/105), the positive rate of P16 was 8.5% (9/105), and the overall consistency rate between P16 and HR-HPV detection was 33.3% (35/105); for HR-HPV infection, the sensitivity and specificity of P16 were 10.4% and 96.4%. In chronic cervical inflammation, the HR-HPV positive rate was 20% (17/85), the positive rate of P16 was 0.0% (0/85); for HR-HPV infection, the sensitivity and specificity of P16 were 0.0% and 100.0%. There was a significant positive correlation between P16 positivity and HPV16/18 in cervical squamous cell carcinoma, adenocarcinoma, and HSIL (P=0.000), while there was no significant correlation in LSIL and chronic cervical inflammation (P>0.05). Conclusion: In cervical squamous cell carcinoma and adenocarcinoma, the consistency of P16 expression and HPV DNA positivity are high, especially in HPV16/18 subtype. There is a good concordance between HR-HPV positivity and P16 protein overexpression. The positive expression of P16 in HSIL may initially reflect HPV infection status. However, in LSIL and chronic cervicitis, P16 expression may not accurately correlate with HPV infection. The inconsistency between P16 and HPV DNA testing could be influenced by multiple factors, including HPV subtypes, histopathological categories, specimen quality, and technical limitations. In clinical practice, it is recommended to conduct comprehensive analysis or employ multiple diagnostic methods to confirm HPV infection status for precise evaluation.

Key words: Cervical lesions, Human papilloma virus, P16 immunohistochemistry, Cervical squamous cell carcinoma, Cervical adenocarcinoma, High-grade squamous intraepithelial lesions, Low-grade squamous intraepithelial lesions, Chronic cervical inflammation, Consistency

中图分类号: 

相关文章

[1] 李雅, 刘慧, 任静静, 李肖甫, 智艳芳. FAM19A4、PAX1及miRNA124-2基因启动子区甲基化在宫颈病变早期诊断中的价值[J]. 中国癌症杂志, 2024, 34(8): 734-744.
[2] 王春桃, 葛安兴, 吴红雁, 张学艳, 杨圣, 袁红香, 程艳萍, 冯延璐, 陆欣苑, 梁戈玉. 不同级别子宫颈病变与lncRNA HOTTIP和H19单核苷酸多态性的关系研究[J]. 中国癌症杂志, 2022, 32(4): 324-334.
[3] 张岩, 陈彤箴, 朱晓丽, 李小秋. 人乳头状瘤病毒相关性口咽鳞状细胞癌的临床病理学特征分析[J]. 中国癌症杂志, 2022, 32(1): 47-53.
[4] 梁 琳 , 万晓春 , 危 平 , 常 彬 , 向礼兵 , 朱琳琳 , 平 波 . 宫颈鳞状上皮FoxM1及Cdc25B细胞核内蛋白水平与高危型HPV感染的相关性研究[J]. 中国癌症杂志, 2020, 30(8): 570-576.
[5] 邱晓阳 , 王少洪 , 郑 璟 , 吴 璇 , 王媛媛 , 刘 君 , 叶才果 . 免疫细胞化学p16/Ki-67双染检测对宫颈细胞 学阴性且HR-HPV阳性病例的分流作用及组织学LSIL的转归预测价值[J]. 中国癌症杂志, 2020, 30(7): 512-518.
[6] 刘梦君,李玉芝,王丽华,常梦然. 鳞状细胞癌抗原检测联合磁共振成像对判断早期宫颈癌盆腔淋巴结转移的临床意义[J]. 中国癌症杂志, 2019, 29(2): 136-141.
[7] 万晓春,周晓燕,平 波,等. 九价HPV疫苗所针对的高危型HPV亚型在宫颈癌及其癌前病变中应用有效性的初步预测[J]. 中国癌症杂志, 2017, 27(7): 552-558.
[8] 段雅晨,陈小军,吴小华. HPV的外周循环血测定及临床意义[J]. 中国癌症杂志, 2017, 27(11): 908-912.
[9] 程静新,刘雅歆,苏伟,袁敏,张瑜,张怡. 新疆南部维吾尔族宫颈鳞癌microRNA研究[J]. 中国癌症杂志, 2014, 24(9): 690-699.
[10] 万晓春,杨慧娟,周晓燕,向礼兵,杨文涛,蔡旭,陆永明,陈颖,平波. 高危型HPV亚型及亚型组合检测宫颈癌及高级别宫颈上皮内瘤变的比较研究[J]. 中国癌症杂志, 2014, 24(5): 342-348.